Introduction
The advent of rationally targeted therapeutics has resulted in a new model of 'cancer precision medicine' whereby drug treatment is matched to the presence or absence of defined molecular characteristics in the tumor of each patient (Yauch and Settleman, 2012) . This approach is fostered by accumulating genomic data -which steadily highlight new potential druggable targets -and it is experimentally supported by preclinical platforms featuring extensive multidimensional annotations, including vast collections of cancer cell lines and patient-derived xenografts (Barretina et al., 2012 , Bertotti et al., 2011 , Garnett et al., 2012 , Sharma et al., 2010 and Tentle et al., 2012 . Notwithstanding the impressive efficacy of some agents in genetically enriched subpopulations, and because of sensible cautionary issues inherent in human experimentation, first-line targeted monotherapy in 'target-positive' patients remains daunting. In fact, it is currently common practice to combine targeted therapies with a chemotherapy backbone, in order to guarantee a 'one-fits-for-all' basis likely to display some generic -but expected -activity. Inevitably, addition of chemotherapeutics confounds the value of molecular lesions in predicting sensitivity or resistance to targeted drugs and precludes lucid evaluation of whether response is attributable to selective blockade of the aberrant target, nonspecific cytotoxic activity of the chemotherapeutic compound(s), or both. Accordingly, it remains to be established whether chemotherapy can intensify the efficacy of targeted agents, or rational inactivation of the dominant oncoprotein in a genetically permissive context suffices to reach a 'point of no return' beyond which chemotherapy becomes superfluous.
These open issues well apply to the case of the MET receptor tyrosine kinase. It is now established that, at least in cellular and animal models, some cancer types rely on high-grade amplification of the MET oncogene -and the ensuing hyper-activation of the encoded kinase -for their growth and survival, and this dependence results in drastic impairment of cancer cell viability upon MET inactivation ('oncogene addiction': Bardelli et al., 2013 , Bertotti et al., 2009 , Comoglio et al., 2008 , McDermott et al., 2007 and Smolen et al., 2006 . Such preclinical findings have been recently confirmed in patients with MET-amplified esophago-gastric adenocarcinomas, who, albeit very rare (2%), have received clinical benefit from therapy with MET small molecule inhibitors or antibodies ( Catenacci et al., 2011 and Lennerz et al., 2011) . MET mainly activates anti-apoptotic pathways. This suggests that tumors exhibiting constitutive MET signaling may be intrinsically poorly sensitive to chemotherapeutics, due to the incessant operativity of MET-dependent survival signals, and that MET inhibition may potentiate the effects of chemotherapy in MET-amplified tumors. However, this assumption has not been challenged experimentally.
Cancers exhibiting MET amplification account for 2-4% of the overall population (COSMIC database:http://www.sanger.ac.uk). In most solid tumors, MET displays normal gene copy number but its expression (and activity) can be transcriptionally induced by cues present in the tumor reactive stroma -such as inflammatory cytokines and pro-angiogenic factors -and by exogenous stress stimuli such hypoxia or ionizing radiations ( De Bacco et al., 2011 , Pennacchietti et al., 2003 and Trusolino et al., 2010 . In this setting, MET upregulation provides pro-survival and pro-invasive advantages that exacerbate the tumor malignant phenotype ('oncogene expedience': Comoglio et al., 2008) . At present, it is not known whether chemotherapeutics, similar to treatments such as radiotherapy ( De Bacco et al., 2011) , can induce MET overexpression. If this were the case, MET inhibition could sensitize cancer cells to chemotherapy in a wide spectrum of tumors, even in contexts in which MET is not genetically amplified.Prompted by these quandaries, we decided to conduct an 'in-cell trial' in which we comparatively assessed the effects of MET inhibition alone, chemotherapy alone, and a combination of chemotherapy and MET-targeted therapy in a panel of cancer cell lines featuring normal or amplified levels of MET.
Material and methods

Cell lines and reagents
A549 (lung adenocarcinoma); NCI-H1975, NCI-H23, NCI-H522, NCI-H460 and HCC-78 (non-small cell lung cancer); NCI-H2452, NCI-H226 and NCI-H28 (mesothelioma); NCI-H441 and NCI-H820 (lung papillary adenocarcinoma); NCI-H322M (bronchio-alveolar carcinoma); SW620, SW48 and DLD1 (colorectal adenocarcinoma); HT29 (rectosigmoid colon adenocarcinoma); MDA-MB-231 and MDA-MB-468 (breast adenocarcinoma); OVCAR8, OVCAR3, A2780 and SKOV3, (ovarian adenocarcinoma); U-118 MG, SNB-75 and SF-268 (glioblastoma); CaKi (kidney carcinoma); HS746T (gastric adenocarcinoma) cell lines were purchased from ATCC (Rockville, MD); EBC-1 (non-small cell lung cancer) were acquired from HSRRB cell bank (Osaka, Japan); GTL16 (gastric adenocarcinoma) are a laboratory batch obtained from limiting dilutions of MKN45 (Giordano et al., 1988) . All cells were kept in culture for less than 8 weeks and used between passage 2 and 20. Cells were grown in recommended media (Sigma Aldrich, St. Louis, MO) supplemented with 50 units/mL penicillin (Sigma Aldrich, St. Louis, MO), 50 mg/mL streptomycin (Sigma Aldrich, St. Louis, MO), 2 mM glutamine (Sigma Aldrich, St. Louis, MO) and 2% or 10% Foetal Bovine Serum (Lonza Sales Ltd, Basel, Switzerland) as indicated. Cells were maintained at 37 °C in 5% CO2 atmosphere. Cisplatin (Sigma Aldrich, St. Louis, MO), 5-fluorouracil (Calbiochem, Merck Millipore, Darmstadt) and PHA-665752 (Tocris Cookson Ltd, Bristol UK) were administered in 2% serum media and used at the indicated concentrations. MV-DN30 was kindly provided by Dr. Petronzelli (Sigma Tau, Pomezia).
Immunoblots
Cells were lysed in EB buffer (10 mM Tris-HCl pH 7.4; 1% TRITON X-100; 5 mM EDTA; 150 mM NaCl; 10% Glycerol; 50 mM NaF; 2 mM Na3VO4; 1 mM Phenylmethanesulfonyl fluoride and a cocktail of protease inhibitors) protein concentration was determined using a BCA Protein Assay kit (Pierce Biotechnology, Rockford, IL). Equal amount of proteins were loaded on to SDS-PAGE gels and transferred to nitrocellulose membrane supports (Hybond C+; Amersham, Buckinghamshire, UK). The membranes were decorated with the following antibodies: mouse monoclonal anti MET DL-21 (Prat et al., 1991) 
Cell viability assay
Cell viability assays were performed in 96 well plates and low serum conditions (2%). Proliferation rates were assessed using Cell Titre Glo Luminescence (Promega Corporation, Madison, Wisconsin, USA). All the experiments were performed at least two times in triplicates or quadruplicates as indicated (Benvenuti et al., 2011) .
RNA extraction and quantitative real time PCR (Q PCR)
Total RNA was isolated using RNeasy Mini Kit (Quiagen, Gmbh, Hilden, Germany) according to manufacturer's instructions. One microgram of RNA was retro-transcribed into cDNA using the High Capacity cDNA Reverse Transcription kit (Applied Biosystems, Foster City, CA) according to manufacturer's instructions. Q PCR was performed using Taq Man Gene Expression Assays for HGF, MET, UBC and GUSB (Applied Biosystems, Foster City, CA) with TaqMan PCR master mix (Applied Biosystems, Foster City, CA) and ABI PRISM 7900HT sequence detection system (Applied Biosystems, Foster City, CA). All samples were analyzed in triplicates.
Apoptosis assay
Treated cells were detached and incubated with FITC-conjugated Annexin V (BD Bioscience). DAPI (Roche Applied Science) was used to identify dead cells. Samples were analyzed on CYAN flow cytometer (CyAn ADP, Beckman Coulter Life Sciences, Brea, CA, USA) equipped with 488 nm, 405 nm and 642 nm solid state lasers. Data were collected and processed using Summit 4.3 software (Beckman Coulter Life Sciences).
In vivo cell transplantation and therapy
All animal procedures were performed according to protocols approved by the Italian Ministry of Health and by the internal Ethical Committee for Animal Experimentation. EBC-1 were injected subcutaneously (1.5 × 106 cells/mouse) into the posterior flanks of 6-week-old immunodeficient nu−/− female mice (Charles River Laboratories, Lecco, Italy). When tumors reached the size of approximately 50 mm3 mice were randomized and assigned to four arms (n = 6) and treated three times per week for 2 months as follow: placebo, MV-DN30 (20 μg/mice), CDDP (24 μg/mice) or MV-DN30 plus CDDP (20 μg/mice and 24 μg/mice respectively). Tumors were measured with a calliper and tumors' volume was calculated at the indicated days using the formula: 4/3π × (d/2)2 × (D/2), where d and D are the minor and the major tumor axis respectively. The general physical status of mice was monitored constantly. At the end of the experiments mice were euthanized and tumors extracted.
Statistical analysis
Experiments were performed in triplicates or quadruplicates as indicated. Standard deviation (SD) or standard error mean (SEM) of each result was reported. All statistical analyses were performed using Excel software (Microsoft Office 2010).
Results
'In-cell trial' design
Typically, preclinical analysis of anticancer compounds involves testing them on a small number of cancer cell lines that may be inadequate to capture the genetic heterogeneity of tumors on a population scale. Moreover, to the best of our knowledge, systematic comparative assessment of the activity of targeted drugs with or without standard chemotherapeutics has not been attempted so far. We therefore decided to gauge the sensitivity of a panel of 28 cancer cell lines, representing diverse tumor types (Supplementary as first line treatment in advanced NSCLC, pre-planned sub-group analysis indicated that progression-free survival was significantly longer for gefitinib than chemotherapy in patients with EGFR mutant tumors, and significantly longer for chemotherapy than gefitinib in patients with EGFR wild-type tumors ( Mok et al., 2009 ). This and other findings contributed to FDA approval of EGFR inhibitor monotherapy for the initial treatment of patients with EGFR mutationpositive metastatic NSCLC. In this vein, again in advanced NSCLC, single-agent inhibition of ALK by crizotinib has been recently shown to be superior to standard chemotherapy in ALK-translocated cases ( Shaw et al., 2013) .
The notion that targeted therapy can outperform standard cytotoxics in genetically defined patient subpopulations does not imply that addition of chemotherapy is unproductive. At least in principle, one could argue that the effects of selective target inhibition can be potentiated by less specific but potentially more aggressive pro-apoptotic insults, such as those triggered by chemotherapeutics. Although empirical, this line of thinking has informed clinical practice, and combination therapies with targeted drugs and conventional agents are now commonplace despite the risk of cumulative toxicity. Examples of FDA-approved combinations include the anti-HER2 monoclonal antibody trastuzumab and the mitotic inhibitor paclitaxel in the first-line treatment of HER2-amplified metastatic breast cancer ( Slamon et al., 2001 ); trastuzumab and a cisplatin-5FU doublet in HER2-positive advanced gastric carcinoma ( Bang et al., 2010) , and the anti-EGFR antibody cetuximab and cisplatin-5FU in head and neck cancer ( Vermorken et al., 2008) . Although most of such combinations have received preclinical experimental validation in xenograft mouse models, their real impact in terms of therapeutic synergy awaits confirmation.
MET inhibitors are currently being tested in several investigational trials, but none of them has been certified for clinical use and conclusions about their efficacy remain immature (Gherardi et al., 2012) . Schematically, studies with MET inhibitors are structured according to two major designs. On one side, recruitment is limited to 'target-positive' casesfor instance, patients with MET-amplified esophago-gastric adenocarcinoma or MET-mutant papillary renal carcinomaand treatment involves targeted monotherapy, usually in patients who have failed prior cycles of conventional chemotherapy. On the other side, recruitment does not occur on a molecular basis and usually MET inhibitors are administered together with standard cytotoxics; trials of this kind are ongoing in NSCLC, colorectal tumors, and triplenegative breast cancer.
Based on these premises we sought to dissect the relative contribution of anti-MET targeted therapy versus standard chemotherapy to tumor growth inhibition and systematically coupled response annotation with the assessment of MET genomic status. To do this we embraced a reductionist approach in cancer cell lines, while trying to accommodate the informative merits of clinical trials. Hence, we selected a reference population -a panel of cancer cell lines of different tumor origin and with different genomic makeups, including some with MET gene amplification -and designed a multiarm study in which each cancer cell line was comparatively challenged with anti-MET monotherapy, single-agent chemotherapy, and combination therapy.
A first series of experiments demonstrated that chemotherapy was overall superior to specific MET blockade in cell lines with normal activity (and genetically wild-type forms) of MET. This is not surprising, as lack of genetic lesions responsible for target hyperactivity usually predicts lack of efficacy of targeted intervention. The unexpected finding is that neutralization of MET, which commonly exerts cytoprotective activities in response to exogenous stress stimuli, did not drastically potentiate the effects of chemotherapy. The reason for this inadequacy is intrinsic to the mode of action of chemotherapeutic agents (at least those tested in this study). Both CDDP and 5FU did not induce transcriptional upregulation of MET, which is one stereotyped mechanism whereby cancer cells adapt to adverse events, including other cytotoxic therapeutic modalities such as ionizing radiation (De Bacco et al., 2011) . The clinical relevance of this observation is straightforward: patients with tumors that are routinely treated with radiotherapy are likely to benefit from MET inhibition, irrespective of MET genetic status. At variance, MET inhibition is probably futile in patients with MET wild-type tumors that receive standard chemotherapy. It cannot be excluded that, in the in vivo situation, chemotherapeutics could activate MET signaling in spite of their inability to boost MET expression. Indeed, the inflammatory phenotype that is commonly produced by standard chemotherapeutics might lead to increased local bioavailability of the MET ligand HGF in the tumor reactive stroma, with consequent paracrine activation of MET and emission of MET-driven pro-survival signals in cancer cells ( Bhowmick et al., 2004) . Our 'in-cell' approach indirectly tackled this issue by performing viability assays in the presence of serum, which contains HGF, recapitulates in part the trophic composition of the tumor microenvironment, and sustains tonic activation of MET signaling. Our repeated observation that MET inhibition does not dramatically influence the outcome of chemotherapy, even in a context of basal MET activity, suggests that interception of MET activity is unlike to reinforce the effects of conventional cytotoxics also in the clinical setting.
Another point of interest of this investigation is that impairment of tumor growth in MET-amplified cells appeared to be saturated by MET inhibition, with no additional activity of chemotherapy. Again, this is somehow unexpected because nullification of MET-regulated survival signals is supposed to exacerbate cell death in the presence of pro-apoptotic stimuli. It is likely that blockade of the dominant oncoprotein in a context of oncogene addiction is so catastrophic that any other insult becomes superfluous. Accordingly, MET obstruction resulted in massive abrogation of MET-dependent downstream signals, with no further impact by addition of cytotoxic agents. When translated into the clinic, this finding supports the use of anti-MET monotherapy in all cases in which a genetic basis for MET hyperactivity is evident, with salient consequences as far as toxicity issues and economic sustainability are concerned.
Cancer cell line-based drug sensitivity screens are emerging as crucial tools to inform therapeutic decisions (Sharma et al., 2010 and Bertotti, 2012) . Their implementation is likely to become increasingly important as the pace of discovery of new investigational compounds is increasing and the rationale for drug combinations receives continuous support from mechanistic studies. Our work provides formal demonstration that MET targeted monotherapy is maximally effective per se whenever tumors exhibit the relevant genetic lesion and is dispensable -even when combined with chemotherapy -in genetically inappropriate contexts. These results add weight to the emerging paradigm that clinical trials need to rely on tumor molecular characterization as a prerequisite for patient stratification and should progressively dismiss post-hoc, evidence-based conclusions.
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